Corinne Bousquet

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3593111/publications.pdf

Version: 2024-02-01

59 papers	4,081 citations	147726 31 h-index	175177 52 g-index
62 all docs	62 docs citations	62 times ranked	6980 citing authors

#	Article	IF	Citations
1	Pharmacologic Normalization of Pancreatic Cancer-Associated Fibroblast Secretome Impairs Prometastatic Cross-Talk With Macrophages. Cellular and Molecular Gastroenterology and Hepatology, 2021, 11, 1405-1436.	2.3	21
2	Phosphorylation of the MNK1 substrate eIF4E is not required for response to acute pancreatitis. Pancreatology, 2021, 21, 677-681.	0.5	2
3	Extracellular Matrices and Cancer-Associated Fibroblasts: Targets for Cancer Diagnosis and Therapy?. Cancers, 2021, 13, 3466.	1.7	55
4	New Insights Into Pancreatic Cancer: Notes from a Virtual Meeting. Gastroenterology, 2021, 161, 785-791.	0.6	5
5	THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G proteinâ€coupled receptors. British Journal of Pharmacology, 2021, 178, S27-S156.	2.7	337
6	Cancer-Associated Fibroblasts: Accomplices in the Tumor Immune Evasion. Cancers, 2020, 12, 2969.	1.7	21
7	<scp>FAK</scp> activity in cancerâ€associated fibroblasts is a prognostic marker and a druggable key metastatic player in pancreatic cancer. EMBO Molecular Medicine, 2020, 12, e12010.	3.3	54
8	The GLP1R Agonist Liraglutide Reduces Hyperglucagonemia Induced by the SGLT2 Inhibitor Dapagliflozin via Somatostatin Release. Cell Reports, 2019, 28, 1447-1454.e4.	2.9	25
9	THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G proteinâ€coupled receptors. British Journal of Pharmacology, 2019, 176, S21-S141.	2.7	519
10	Latest Advances in Targeting the Tumor Microenvironment for Tumor Suppression. International Journal of Molecular Sciences, 2019, 20, 4719.	1.8	48
11	Differential Regulation of the Three Eukaryotic mRNA Translation Initiation Factor (eIF) 4Gs by the Proteasome. Frontiers in Genetics, 2019, 10, 254.	1.1	10
12	Interâ€and intraâ€tumoural heterogeneity in cancerâ€associated fibroblasts of human pancreatic ductal adenocarcinoma. Journal of Pathology, 2019, 248, 51-65.	2.1	215
13	Stromal protein Î²ig-h3 reprogrammes tumour microenvironment in pancreatic cancer. Gut, 2019, 68, 693-707.	6.1	79
14	eIF4A inhibition circumvents uncontrolled DNA replication mediated by 4E-BP1 loss in pancreatic cancer. JCI Insight, 2019, 4, .	2.3	25
15	Somatostatin receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide To Pharmacology CITE, 2019, 2019, .	0.2	1
16	International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature. Pharmacological Reviews, 2018, 70, 763-835.	7.1	163
17	Targeting the NRG1/HER3 pathway in tumor cells and cancer-associated fibroblasts with an anti-neuregulin 1 antibody inhibits tumor growth in pre-clinical models of pancreatic cancer. Cancer Letters, 2018, 432, 227-236.	3.2	37
18	Identification of two cancer-associated fibroblast markers revealing stromal heterogeneity in sustaining cancer progression and chemoresistance. Translational Cancer Research, 2018, 7, S718-S721.	0.4	3

#	Article	IF	Citations
19	Focal Adhesion Kinase: A promising therapeutic target in pancreatic adenocarcinoma. Clinics and Research in Hepatology and Gastroenterology, 2017, 41, 246-248.	0.7	4
20	Cancer-associated fibroblast-derived annexin A6+ extracellular vesicles support pancreatic cancer aggressiveness. Journal of Clinical Investigation, 2016, 126, 4140-4156.	3.9	169
21	Pancreatic cancer cell invasion: mesenchymal switch or just hitchhiking?. Translational Cancer Research, 2016, 5, S1093-S1097.	0.4	4
22	Pharmacological targeting of the protein synthesis <scp>mTOR</scp> /4Eâ€•<scp>BP</scp> 1 pathway in cancerâ€associated fibroblasts abrogates pancreatic tumourÂchemoresistance. EMBO Molecular Medicine, 2015, 7, 735-753.	3.3	164
23	Imbalanced splicing in MAPK signaling sustains Ras-induced transformation. Clinics and Research in Hepatology and Gastroenterology, 2015, 39, 155-156.	0.7	1
24	Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16. Gastroenterology, 2015, 148, 1452-1465.	0.6	36
25	Abstract B16: Progastrin activates colon fibroblasts and participates to the dialogue between tumor epithelial cells and stromal fibroblasts in colorectal cancer. , 2015, , .		0
26	Abstract 402: Pasireotide reduces chemoresistance in pancreatic tumor cells by inhibiting the synthesis and secretion of growth factors from tumor associated fibroblasts. , 2015, , .		0
27	Pancreatic cell plasticity and cancer initiation induced by oncogenic Kras is completely dependent on wild-type PI 3-kinase p110Î±. Genes and Development, 2014, 28, 2621-2635.	2.7	108
28	Somatostatin analogs: does pharmacology impact antitumor efficacy?. Trends in Endocrinology and Metabolism, 2014, 25, 115-127.	3.1	50
29	Hypoxia Induces VEGF-C Expression in Metastatic Tumor Cells via a HIF-1Î±-Independent Translation-Mediated Mechanism. Cell Reports, 2014, 6, 155-167.	2.9	102
30	4E-BP restrains eIF4E phosphorylation. Translation, 2013, 1, e25819.	2.9	27
31	Changes in Translational Control after Pro-Apoptotic Stress. International Journal of Molecular Sciences, 2013, 14, 177-190.	1.8	13
32	Contribution of HIF-1Î± in 4E-BP1 Gene Expression. Molecular Cancer Research, 2013, 11, 54-61.	1.5	19
33	A Switch of G Protein-Coupled Receptor Binding Preference from Phosphoinositide 3-Kinase (PI3K)â€“p85 to Filamin A Negatively Controls the PI3K Pathway. Molecular and Cellular Biology, 2012, 32, 1004-1016.	1.1	32
34	Current Scientific Rationale for the Use of Somatostatin Analogs and mTOR Inhibitors in Neuroendocrine Tumor Therapy. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 727-737.	1.8	79
35	Inflammation triggers and sustains a pathological threshold of Ras activity necessary to induce pancreatic tumorigenesis. Clinics and Research in Hepatology and Gastroenterology, 2012, 36, 527-529.	0.7	0
36	Control of contact-inhibition by 4E-BP1 upregulation. Cell Cycle, 2010, 9, 1241-1245.	1.3	14

#	Article	IF	Citations
37	NAD(P)H Quinone-Oxydoreductase 1 Protects Eukaryotic Translation Initiation Factor 4GI from Degradation by the Proteasome. Molecular and Cellular Biology, 2010, 30, 1097-1105.	1.1	34
38	Netrin-1 Mediates Early Events in Pancreatic Adenocarcinoma Progression, Acting on Tumor and Endothelial Cells. Gastroenterology, 2010, 138, 1595-1606.e8.	0.6	102
39	Abstract 3149: 4E-BP1 loss of function in pancreatic carcinogenesis. , 2010, , .		0
40	Thrombospondin-1 is a critical effector of oncosuppressive activity of sst2 somatostatin receptor on pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 17769-17774.	3.3	33
41	Targeting the sphingolipid metabolism to defeat pancreatic cancer cell resistance to the chemotherapeutic gemcitabine drug. Molecular Cancer Therapeutics, 2009, 8, 809-820.	1.9	117
42	4E-BP1 is a target of Smad4 essential for TGFÎ²-mediated inhibition of cell proliferation. EMBO Journal, 2009, 28, 3514-3522.	3.5	54
43	Antitumor effects of somatostatin. Molecular and Cellular Endocrinology, 2008, 286, 230-237.	1.6	156
44	Direct binding of p85 to sst2 somatostatin receptor reveals a novel mechanism for inhibiting PI3K pathway. EMBO Journal, 2006, 25, 3943-3954.	3.5	76
45	Somatostatin receptors as tools for diagnosis and therapy: Molecular aspects. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2005, 19, 535-551.	1.0	30
46	Molecular Signaling of Somatostatin Receptors. Annals of the New York Academy of Sciences, 2004, 1014, 121-131.	1.8	138
47	Somatostatin Receptor Signaling via Protein Tyrosine Phosphatases. , 2004, , 159-167.		0
48	Somatostatin receptor subtype 2 sensitizes human pancreatic cancer cells to death ligand-induced apoptosis. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 155-160.	3.3	117
49	Transfection of Pancreatic-Derived Î²-Cells with a Minigene Encoding for Human Glucagon-Like Peptide-1 Regulates Glucose-Dependent Insulin Synthesis and Secretion. Endocrinology, 2002, 143, 3529-3539.	1.4	20
50	Antiproliferative Effect of Somatostatin and Analogs. Chemotherapy, 2001, 47, 30-39.	0.8	111
51	Signal transduction of somatostatin receptors negatively controlling cell proliferation. Journal of Physiology (Paris), 2000, 94, 205-210.	2.1	93
52	Direct regulation of pituitary proopiomelanocortin by STAT3 provides a novel mechanism for immuno-neuroendocrine interfacing. Journal of Clinical Investigation, 2000, 106, 1417-1425.	3.9	95
53	Inhibitory roles for SHP-1 and SOCS-3 following pituitary proopiomelanocortin induction by leukemia inhibitory factor. Journal of Clinical Investigation, 1999, 104, 1277-1285.	3.9	96
54	Critical Role for STAT3 in Murine Pituitary Adrenocorticotropin Hormone Leukemia Inhibitory Factor Signaling. Journal of Biological Chemistry, 1999, 274, 10723-10730.	1.6	55

#	Article	IF	Citations
55	Pituitary Corticotroph SOCS-3: Novel Intracellular Regulation of Leukemia-Inhibitory Factor-Mediated Proopiomelanocortin Gene Expression and Adrenocorticotropin Secretion. Molecular Endocrinology, 1998, 12, 954-961.	3.7	79
56	sst2 Somatostatin Receptor Mediates Negative Regulation of Insulin Receptor Signaling through the Tyrosine Phosphatase SHP-1. Journal of Biological Chemistry, 1998, 273, 7099-7106.	1.6	99
57	Pituitary Corticotroph SOCS-3: Novel Intracellular Regulation of Leukemia-Inhibitory Factor-Mediated Proopiomelanocortin Gene Expression and Adrenocorticotropin Secretion. Molecular Endocrinology, 1998, 12, 954-961.	3.7	31
58	A Common Pro-opiomelanocortin-binding Element Mediates Leukemia Inhibitory Factor and Corticotropin-releasing Hormone Transcriptional Synergy. Journal of Biological Chemistry, 1997, 272, 10551-10557.	1.6	65
59	Anti-metastatic potential of somatostatin analog SOM230: Indirect pharmacological targeting of pancreatic cancer-associated fibroblasts. Oncotarget, 0, 7, 41584-41598.	0.8	36